Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DVA 
DaVita HealthCare Partners Inc (DVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: DVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -28.7% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.24B USD | Price to earnings Ratio 14.27 | 1Y Target Price 163.26 |
Price to earnings Ratio 14.27 | 1Y Target Price 163.26 | ||
Volume (30-day avg) 1221552 | Beta 0.99 | 52 Weeks Range 125.64 - 179.60 | Updated Date 04/1/2025 |
52 Weeks Range 125.64 - 179.60 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.31% | Operating Margin (TTM) 13.74% |
Management Effectiveness
Return on Assets (TTM) 7.15% | Return on Equity (TTM) 51.74% |
Valuation
Trailing PE 14.27 | Forward PE 13.62 | Enterprise Value 23238439000 | Price to Sales(TTM) 0.95 |
Enterprise Value 23238439000 | Price to Sales(TTM) 0.95 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA 8.53 | Shares Outstanding 80000000 | Shares Floating 41226400 |
Shares Outstanding 80000000 | Shares Floating 41226400 | ||
Percent Insiders 48.63 | Percent Institutions 49.83 |
Analyst Ratings
Rating 3.1 | Target Price 161.59 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 8 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
DaVita HealthCare Partners Inc
Company Overview
History and Background
DaVita Inc. was founded in 1999, though its roots trace back to National Medical Care, established in 1950. It evolved to become a leading provider of kidney care services, including dialysis and related treatments. Significant milestones include acquisitions and expansions that solidified its market position.
Core Business Areas
- Kidney Care Services: DaVita provides dialysis services, including in-center hemodialysis and peritoneal dialysis, as well as home dialysis programs. It also offers related lab services and vascular access management.
Leadership and Structure
DaVita is led by Javier Rodriguez (CEO). The organizational structure is based on operational regions and functional departments like clinical services, finance, and marketing.
Top Products and Market Share
Key Offerings
- Dialysis Services: DaVita's primary service is dialysis, offered in-center and at home. DaVita has ~37% of the dialysis market share in the United States (estimated). Major competitors include Fresenius Medical Care and U.S. Renal Care.
Market Dynamics
Industry Overview
The dialysis industry is characterized by high barriers to entry, driven by regulatory requirements and the need for specialized infrastructure. The industry is consolidating with a few major players dominating the market.
Positioning
DaVita is one of the largest dialysis service providers in the U.S. It maintains a competitive advantage through its established network of clinics, clinical expertise, and focus on patient care.
Total Addressable Market (TAM)
The global dialysis market is projected to reach USD 124.5 billion by 2030. DaVita captures a significant portion of the U.S. dialysis market, positioning it well to capitalize on this large and growing TAM.
Upturn SWOT Analysis
Strengths
- Large network of dialysis centers
- Strong brand recognition
- Established relationships with physicians and hospitals
- Focus on clinical quality
Weaknesses
- High operating costs
- Dependence on government reimbursement (Medicare)
- Exposure to regulatory changes
- Negative publicity related to billing practices
Opportunities
- Expanding home dialysis programs
- Acquiring smaller dialysis providers
- Developing integrated care models
- Growing demand for dialysis services due to aging population and increasing diabetes rates
Threats
- Changes in government reimbursement policies
- Increased competition from other dialysis providers
- Technological advancements that could disrupt the dialysis market
- Rising operating costs
Competitors and Market Share
Key Competitors
- FMS
- US Renal Care
- NPHS
Competitive Landscape
DaVita competes with Fresenius Medical Care (FMS) as the two largest players. Smaller regional players and independent dialysis centers also contribute to the competitive landscape. DaVita is focused on patient care quality and innovation.
Major Acquisitions
Reliant Medical Group
- Year: 2016
- Acquisition Price (USD millions): 400
- Strategic Rationale: Expanded DaVita's integrated care capabilities.
Growth Trajectory and Initiatives
Historical Growth: DaVita has grown through acquisitions and organic expansion of its dialysis center network.
Future Projections: Future growth projections depend on factors such as government reimbursement policies, competition, and the overall demand for dialysis services. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding home dialysis programs and focusing on integrated care models to improve patient outcomes and reduce costs.
Summary
DaVita is a leading dialysis provider with a strong market share, but faces challenges from reimbursement pressures and operating costs. Its strengths lie in its large network and focus on patient care. Future growth hinges on expanding home dialysis and adapting to regulatory changes.
Similar Companies
- FMS
- NPHS
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DaVita HealthCare Partners Inc
Exchange NYSE | Headquaters Denver, CO, United States | ||
IPO Launch date 1995-10-31 | CEO & Executive Director Mr. Javier J. Rodriguez | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 76000 | Website https://www.davita.com |
Full time employees 76000 | Website https://www.davita.com | ||
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.